|[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]|
AUDIENCE: Risk Manager, Laboratory, Infectious Disease
ISSUE: bioMérieux, Inc. VITEK 2 Gram Negative Susceptibility Cards that contain Piperacillin/Tazobactam are reporting incorrect results for testing the susceptibility of E. coli and K. pneumoniae to this drug. For E. coli, both falsely-resistant and falsely-susceptible results have been reported; for K. pneumoniae, only falsely resistant results have been observed. Incorrect results could potentially lead to patients being inappropriately treated with Piperacillin/Tazobactam, which could cause serious injury or death.
BACKGROUND: These cards are used in clinical laboratories to perform antimicrobial susceptibility testing as part of the VITEK System.
RECOMMENDATION: The company issued instructions to their customers to complete alternative test confirmations. See the Recall Notice for additional information.
Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:
Read the MedWatch safety alert, including a link to the Recall Notice, at:
Tell us how we are doing:
You are encouraged to report all serious adverse events and product quality problems to FDA MedWatch at www.fda.gov/medwatch/report.htm
Follow MedWatch on Twitter
Update your subscriptions, modify your e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact support@xxxxxxxxxxxxxxx.
This service is provided to you at no charge by U.S. Food & Drug Administration (FDA).
U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420